Investigating the use of Baricitinib to treat cognitive impairment after Long COVID
REVERSE-Long COVID: A Multicenter Randomized, Placebo-Controlled Clinical Trial of Immunomodulation (with Baricitinib) for Long COVID Related ADRD
This study is looking for people who have memory and thinking problems after COVID-19 to see if a medication called Baricitinib can help improve their brain function and reduce symptoms of Alzheimer's and related conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project ID | NIH-11004164 on NIH RePORTER |
What this research studies
This research focuses on patients experiencing cognitive impairment and related conditions following COVID-19, known as Long COVID. It aims to evaluate the effectiveness of Baricitinib, an immunomodulator, in reducing symptoms of Alzheimer's Disease and Related Dementias (ADRD) and improving overall cognitive function. Participants will be randomly assigned to receive either Baricitinib or a placebo, allowing researchers to assess the drug's impact on cognitive and physical health. The study will involve multiple medical centers to gather diverse data and ensure robust results.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing cognitive impairment or symptoms of ADRD following a COVID-19 infection.
Not a fit: Patients who have not experienced cognitive impairment or who are not affected by Long COVID may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from cognitive impairments related to Long COVID.
How similar studies have performed: Other research has shown promising results in using immunomodulators for similar conditions, indicating potential for success in this approach.
Where this research is happening
Nashville, United States
- Vanderbilt University Medical Center — Nashville, United States (Active)
Researchers
- Principal investigator: Ely, E Wesley — Vanderbilt University Medical Center
- Study coordinator: Ely, E Wesley
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.